Debiopharm and Aurigene dual c-src / jak inhibitors

New Drug Approvals

SCHEMBL2237115.pngSTR3str4

Debio 1142

Jak2 tyrosine kinase inhibitor; Src tyrosine kinase inhibitor

N-[4-methyl-3-[2-[4-(4-methylpiperazin-1-yl)anilino]-5-oxo-7,8-dihydropyrido[4,3-d]pyrimidin-6-yl]phenyl]-3-(trifluoromethyl)benzamide

Molecular Formula: C33H32F3N7O2
Molecular Weight: 615.64809 g/mol
1332328-01-4
Benzamide, N-​[3-​[7,​8-​dihydro-​2-​[[4-​(4-​methyl-​1-​piperazinyl)​phenyl]​amino]​-​5-​oxopyrido[4,​3-​d]​pyrimidin-​6(5H)​-​yl]​-​4-​methylphenyl]​-​3-​(trifluoromethyl)​-

Debiopharm S.A., Aurigene Discovery Technologies Ltd.

ALLISTER Andrès MC, Maximilien Murone,Saumitra Sengupta, Shankar Jayaram Shetty

https://www.google.co.in/patents/WO2011101806A1?cl=en

Bicyclic compounds and their uses as dual c-src / jak inhibitors

STR3

Apr. 14 /PR Newswire/ –Debiopharm and Aurigene Sign Agreement for the Development and Commercialisation of Debio 1142, a Novel Inhibitor of an Undisclosed Oncology Pathway

LAUSANNE, Switzerland and BANGALORE, India, April 14, 2011 /PRNewswire/ — Debiopharm Group(TM) (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies Ltd (Aurigene), a Bangalore-based drug discovery company, signed on March 23, 2011 an option and exclusive worldwide license agreement concerning the development and commercialisation of…

View original post 433 more words

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s